- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 19
The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 19, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 19.
Number 5: A white paper from the Association for Accessible Medicines says that brand-name drug products are behind high prescription drug costs, and that those high costs endanger patients’ health.
Number 4: At last week’s 13th annual congress of the European Crohn's and Colitis Organisation, researchers presented findings from several studies investigating the efficacy of 2 biosimilar infliximab products.
Number 3: Investigators have released data from a 26-week open label extension of the NOR-SWITCH trial in patients with inflammatory bowel disease.
Number 2: The Patients for Biologic Safety and Access, a patient advocacy group, called on the FDA to revise its materials on biosimilars. However, some patient groups are calling PBSA’s stance into question.
Number 1: Express Scripts and Walgreens Boots are expanding their purchasing efforts to include specialty medications, such as biologics and biosimilars.
Also this week, contributor Amanda Forys, of Xcenda, explained what biosimilar manufacturers need to know about changes to the 340B Drug Pricing Program.
Finally, last week, our e-newsletter asked for your thoughts on when nonmedical substitution will become a reality in the United States.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
